CtDNA is also more specific to tumour load compared to serum-based protein biomarkers such as cancer antigen 125 in ovarian cancer patients [16], and can be used for tumours for which no serum-based protein biomarkers are available, as is the case for ESCC [34]. This evidence concerns the gene MUC16 and esophageal squamous cell carcinoma.